Summit Therapeutics Inc. (SMMT) Ownership
SMMT ownership summary
as of October 17, 2026- Institutions
- 17.6% of shares outstanding
- Insiders
- 80.87% of shares outstanding
- Shares outstanding
- 797.7M
- Float
- 153.9M shares available to trade
- Short interest
- 26.30% 41.2M shares short
- Days to cover
- 5.51 short interest up 0.2% vs prior month
- Institutions 17.60%
- Insiders 80.87%
- Other investors 1.53%
SMMT top institutional holders
1 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP | 0.07% | 521K | $7.6M | −82,594 (−13.7%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 1, 0 holders added 0 shares and 1 cut 83K.
SMMT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 0.47% | 3.7M | $54.4M | −10,827 (−0.3%) | August 31, 2026 |
| 2 | State Street® SPDR® S&P® Biotech ETF | 0.46% | 3.7M | $53.5M | −69,900 (−1.9%) | September 30, 2026 |
| 3 | T. Rowe Price Health Sciences | 0.40% | 3.2M | $46.8M | −191,400 (−5.6%) | August 31, 2026 |
| 4 | Vanguard Small Cap Index | 0.34% | 2.7M | $39.2M | −642 (−0.0%) | August 31, 2026 |
| 5 | Fidelity Growth Company Fund | 0.26% | 2.0M | $30.0M | −601,600 (−22.7%) | August 31, 2026 |
| 6 | Vanguard MStar Small Cap Value Index | 0.21% | 1.7M | $24.9M | +1,358 (+0.1%) | August 31, 2026 |
| 7 | iShares Biotechnology ETF | 0.15% | 1.2M | $17.4M | −9,008 (−0.8%) | September 30, 2026 |
| 8 | Fidelity Select Biotechnology | 0.13% | 1.1M | $15.6M | — | August 31, 2026 |
| 9 | abrdn Healthcare Investors | 0.13% | 1.1M | $15.5M | — | August 31, 2026 |
| 10 | International Biotechnology Ord | 0.10% | 836K | $12.2M | +570,874 (+215.4%) | June 30, 2026 |
| 11 | iShares Russell Mid-Cap Growth ETF | 0.10% | 781K | $11.4M | −834 (−0.1%) | September 30, 2026 |
| 12 | Fidelity Extended Market Index | 0.10% | 762K | $11.1M | −9,692 (−1.3%) | August 31, 2026 |
| 13 | Fidelity Select Health Care | 0.09% | 750K | $11.0M | −50,000 (−6.2%) | August 31, 2026 |
| 14 | abrdn Life Sciences Investors | 0.08% | 676K | $9.9M | — | August 31, 2026 |
| 15 | iShares Nasdaq US Biotech ETF USD Acc | 0.08% | 652K | $9.5M | +5,416 (+0.8%) | September 30, 2026 |
| 16 | Fidelity Series Growth Company | 0.08% | 599K | $8.8M | −50,100 (−7.7%) | August 31, 2026 |
| 17 | iShares Russell Mid-Cap ETF | 0.07% | 573K | $8.4M | +1,064 (+0.2%) | September 30, 2026 |
| 18 | Candriam Eqs L Biotech C USD Cap | 0.07% | 541K | $7.9M | — | March 31, 2026 |
| 19 | Fidelity Mid Cap Index | 0.07% | 519K | $7.6M | +3,745 (+0.7%) | August 31, 2026 |
| 20 | Simplify Health Care ETF | 0.06% | 510K | $7.5M | — | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
SMMT insider transactions
latest 7| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2025-10-21 | Mahkam Zanganeh | Buy | $18.74 | 26,680 | $499,983 |
| 2025-10-21 | Robert W Duggan | Buy | $18.74 | 26,680 | $499,983 |
| 2025-10-21 | Yu Xia | Buy | $18.74 | 533,617 | $10.0M |
| 2025-09-11 | Mahkam Zanganeh | Buy | $18.07 | 5,000 | $90,350 |
| 2025-09-11 | Robert W Duggan | Buy | $18.07 | 5,000 | $90,350 |
| 2025-09-10 | Mahkam Zanganeh | Buy | $17.68 | 333,394 | $5.9M |
| 2025-09-10 | Robert W Duggan | Buy | $17.68 | 333,394 | $5.9M |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
SMMT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns SMMT
Institutional investors own 17.6% of Summit Therapeutics's shares and insiders 80.87%. The largest holder is Susquehanna International Group, LLP with 0.07% of the shares (521K), as of June 30, 2026. Among the top 1 institutions, 0 added shares and 1 reduced their stake in the latest filings. Short interest is 26.30% of the float, or 5.51 days of average trading volume. The share count rose 1,796.4% since 2014.
Related: SMMT analyst forecast, SMMT key metrics. See the SMMT stock overview for the latest quote and news.
SMMT ownership FAQ
Who owns the most Summit Therapeutics stock?
The largest shareholders of Summit Therapeutics are Susquehanna International Group, LLP (0.07%).
What percentage of Summit Therapeutics is owned by institutions?
Institutions hold 17.6% of Summit Therapeutics's shares outstanding; insiders hold 80.87%.
Which funds own Summit Therapeutics?
The largest fund holders of Summit Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (0.47%), State Street® SPDR® S&P® Biotech ETF (0.46%), T. Rowe Price Health Sciences (0.40%), Vanguard Small Cap Index (0.34%), Fidelity Growth Company Fund (0.26%).
What is Summit Therapeutics's short interest?
41.2M shares of Summit Therapeutics were sold short, 26.30% of the float; at the average daily volume it would take 5.51 days to cover.
Are insiders buying or selling Summit Therapeutics?
Of the latest 7 reported insider transactions in Summit Therapeutics (since September 10, 2025), 7 were purchases and 0 were sales.
How many shares of Summit Therapeutics are outstanding?
Summit Therapeutics has 797.7M shares outstanding, of which 153.9M are in the public float.